Featured Research

from universities, journals, and other organizations

Lung cancer study focuses on a more targeted treatment option

Date:
June 24, 2014
Source:
Houston Methodist
Summary:
A new study will compare an emerging immunotherapy drug to an existing chemotherapy drug and look at the effects both drugs have on the development of non-small cell lung cancer, a type of cancer which makes up about 85 percent of lung cancer cases.

A new study offered at Houston Methodist Hospital will compare an emerging immunotherapy drug to an existing chemotherapy drug and look at the effects both drugs have on the development of non-small cell lung cancer, a type of cancer which makes up about 85 percent of lung cancer cases. Lung cancer is the second most common malignancy in the United States.

For many years, researchers had hoped to find a way to manipulate the immune system to attack tumors. With the development of immune checkpoint inhibitors, cancer researchers are beginning to see evidence of sustained responses to a fairly nontoxic therapy that works completely different from chemotherapy. With so many different studies looking at immunotherapy, this particular study offered at Houston Methodist Hospital is important because it hopes to see how the new therapy stacks up against standard chemotherapy.

"For the first time we are using targeted therapy and relying on the patient's immune system to help fight the cancer," said Eric Bernicker, M.D., thoracic medical oncologist with Houston Methodist Cancer Center and the study's principal investigator. "From a research standpoint we need to be able to offer new options to our patients using less toxic therapies, with fewer side effects."

Immunotherapy could soon change the way oncologists are treating lung cancer. Immunotherapy stimulates the body's own immune system to attack cancer cells through humanmade proteins. Unlike normal chemotherapy, once immunotherapy is underway it has an ongoing impact in the body even when the drug is not being administered.

To test this research question, individuals will be randomly assigned by a computer to one of the following intervention groups. When the individual is randomized into the study, neither the patient nor study doctor may choose the group assigned. This is an open-label study, meaning the study doctor and patient will know which treatment is assigned.

"Lung cancer research has expanded because of the tremendous strides that have been made in identifying molecular mutations that drive the tumor development," Bernicker said. "Researchers are beginning to recognize that the immune system can be better harnessed to help fight the disease."


Story Source:

The above story is based on materials provided by Houston Methodist. Note: Materials may be edited for content and length.


Cite This Page:

Houston Methodist. "Lung cancer study focuses on a more targeted treatment option." ScienceDaily. ScienceDaily, 24 June 2014. <www.sciencedaily.com/releases/2014/06/140624135900.htm>.
Houston Methodist. (2014, June 24). Lung cancer study focuses on a more targeted treatment option. ScienceDaily. Retrieved August 23, 2014 from www.sciencedaily.com/releases/2014/06/140624135900.htm
Houston Methodist. "Lung cancer study focuses on a more targeted treatment option." ScienceDaily. www.sciencedaily.com/releases/2014/06/140624135900.htm (accessed August 23, 2014).

Share This




More Health & Medicine News

Saturday, August 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins